September 1, 2010
Gilead Provides Update on $5 Billion Stock Repurchase Program

August 19, 2010
Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R)

July 30, 2010
Gilead Closes Sale of $2.2 Billion of Convertible Senior Notes

July 27, 2010
Gilead Prices $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock

July 26, 2010
Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock

July 20, 2010
Gilead Sciences Announces Second Quarter 2010 Financial Results

July 14, 2010
Gilead Sciences Files Patent Infringement Lawsuit Against Lupin Limited

July 13, 2010
Gilead Sciences to Release Second Quarter 2010 Financial Results on Tuesday, July 20, 2010

June 25, 2010
Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

June 18, 2010
Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority

June 10, 2010
Gilead Sciences Announces Notification of ANDA Filing for Ranexa(R)

June 9, 2010
Gilead Sciences to Present at Two Upcoming Investor Conferences

June 8, 2010
John G. McHutchison, MD, to Join Gilead Sciences as Senior Vice President, Liver Disease Therapeutics

June 4, 2010
Gilead Sciences and ADAP Crisis Task Force Announce New Initiatives to Support AIDS Drug Assistance Programs (ADAPs)

June 2, 2010
Gilead Sciences to Present at the Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9

May 27, 2010
Gilead Sciences to Present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference on Thursday, June 3

May 19, 2010
Gilead Sciences to Present at the 2010 Citi Investment Research Global Health Care Conference on Wednesday, May 26

May 11, 2010
Gilead Announces $5 Billion Share Repurchase Program

May 6, 2010
Gilead Sciences to Present at the Banc of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13

April 27, 2010
Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278

April 20, 2010
Gilead Sciences Announces Record First Quarter 2010 Financial Results

April 20, 2010
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278

April 19, 2010
Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis C

April 13, 2010
Gilead Sciences to Release First Quarter 2010 Financial Results on Tuesday, April 20, 2010

April 12, 2010
Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily "Quad" Regimen for HIV

March 17, 2010
Gilead Sciences to Present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24

March 4, 2010
Gilead Sciences to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11

February 22, 2010
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa

February 17, 2010
Gilead's Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study

February 2, 2010
Gilead Sciences to Present at the 12th Annual BIO CEO Investor Conference on Tuesday, February 9

January 29, 2010
Gilead Announces Share Repurchase Program

January 28, 2010
Per Wold-Olsen Joins Gilead Sciences' Board of Directors

January 27, 2010
Gilead Sciences Announces Notification of ANDA Filing for Viread®

January 26, 2010
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results

January 19, 2010
Gilead Sciences to Release Fourth Quarter and Year End 2009 Financial Results on Tuesday, January 26, 2010

January 6, 2010
Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad"Regimen Meets 24-Week Primary Objective

January 4, 2010
Gilead Sciences to Present at Two Upcoming Investor Conferences